6-phenylpyrimidine-4-carboxylic acid methyl ester | 74647-38-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-phenylpyrimidine-4-carboxylic acid methyl ester
• 英文别名: methyl 6-phenylpyrimidine-4-carboxylate
• CAS: 74647-38-4
• 化学式: C₁₂H₁₀N₂O₂
• 分子量: 214.224
• InChiKey: RIHBEWGMRKBAOH-UHFFFAOYSA-N

物化性质

• 熔点：
  71-73 °C(Solv: ethyl ether (60-29-7); hexane (110-54-3))
• 沸点：
  383.8±30.0 °C(Predicted)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-phenylpyrimidine-4-carboxylic acid methyl ester 在 ammonium hydroxide 作用下， 以 甲醇 为溶剂， 反应 10.0h， 以65%的产率得到6-phenylpyrimidine-4-carboxamide
  参考文献：
  名称：

  Studies on pyrimidine derivatives. XVI. Site selectivity in the homolytic substitution of simple pyrimidines.

  摘要：

  在2位和4位均处于游离状态的嘧啶衍生物中，它们与在氧化还原系统中生成的自由基反应时表现出位点选择性。即，6-苯基-(I)、6-甲基嘧啶(XV)和5, 6, 7, 8-四氢喹唑啉(XVII)与诸如RCO、R2NCO、EtOCO和CH2OH等自由基反应，主要生成4位取代产物。除了I与N,N-二甲基氨基甲酰基自由基反应外，未观察到相应的2位取代异构体的形成。

  DOI：

  10.1248/cpb.28.571
• 作为产物：
  描述：

  苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 四(三苯基膦)钯 、 potassium carbonate 、 三乙胺 作用下， 50.0~90.0 ℃ 、500.01 kPa 条件下， 反应 20.0h， 生成 6-phenylpyrimidine-4-carboxylic acid methyl ester
  参考文献：
  名称：

  Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s Disease

  摘要：

  We report on the development of a series of pyrimidine carboxylic acids that are potent and selective inhibitors of kynurenine monooxygenase and competitive for kynurenine. We describe the SAR for this novel series and report on their inhibition of KMO activity in biochemical and cellular assays and their selectivity against other kynurenine pathway enzymes. We describe the optimization process that led to the identification of a program lead compound with a suitable ADME/PK profile for therapeutic development. We demonstrate that systemic inhibition of KMO in vivo with this lead compound provides pharmacodynamic evidence for modulation of kynurenine pathway metabolites both in the periphery and in the central nervous system.

  DOI：

  10.1021/jm501350y

文献信息

• TRICYCLIC HETEROCYCLIC COMPOUNDS
  申请人：Dhar T.G. Murali

  公开号：US20120214767A1

  公开（公告）日：2012-08-23

  Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X 1 , X 2 , X 3 , W, Q 1 , Q 2 , and G 2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及公式（I）的化合物或其立体异构体或盐，其中：X1、X2、X3、W、Q1、Q2和G2在此定义。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或障碍方面有用，例如自身免疫性疾病和血管疾病。
• Tricyclic heterocyclic compounds
  申请人：Bristol-Myers Squibb Company

  公开号：EP2592071A1

  公开（公告）日：2013-05-15

  Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  公开了式 (I) 的化合物 或其立体异构体或盐，其中X1、X2、X3、W、Q1、Q2 和 G2 在本文中定义。还公开了将此类化合物用作 G 蛋白偶联受体 S1P1 选择性激动剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗、预防或减缓各种治疗领域的疾病或失调，如自身免疫性疾病和血管疾病。
• SAKAMOTO TAKAO; SAKASAI TAKEJI; YAMANAKA HIROSHI, CHEM. AND PHARM. BULL., 1980, 28, NO 2, 571-577
  作者：SAKAMOTO TAKAO、 SAKASAI TAKEJI、 YAMANAKA HIROSHI

  DOI：——

  日期：——
• CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：CHDI, Inc.

  公开号：EP2331095A1

  公开（公告）日：2011-06-15
• KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Courtney Stephen Martin

  公开号：US20140329795A1

  公开（公告）日：2014-11-06

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.